Cresemba (isavuconazonium sulfate) Patient Assistance Program
Don’t let the high cost of brand triazole antifungal disrupt your invasive fungal infection treatment. We help eligible patients access Cresemba (isavuconazonium sulfate capsules and IV) for as little as $69.95 per month through the manufacturer’s Patient Assistance Program.
- Clear & Transparent Pricing
- Paperwork & Doctor-Coordination
- Comprehensive Support: From Application to Entire Journey
- Annual Re-certification And Refills Management
- Medicare Part D Patients Accepted
Key Takeaways:
- Cresemba (isavuconazonium sulfate) is FDA-approved for invasive aspergillosis and invasive mucormycosis in adults and pediatric patients 1 year and older. Broad-spectrum triazole antifungal — activity against Aspergillus, Mucorales, Candida, Cryptococcus, and dimorphic molds. Available as oral capsules and IV — same dosing between routes.
- Without assistance, Cresemba costs commonly run approximately $6,000–$10,000 per month.
- Through AffordMyPrescriptions, qualifying patients can access Cresemba for a flat $69.95 per month.
- Other triazole antifungals: voriconazole (Vfend — generic, gold standard for aspergillosis but with QT prolongation, hepatotoxicity, visual disturbances, drug interactions), posaconazole (Noxafil — generic), itraconazole (Sporanox — generic), fluconazole (Diflucan — generic, limited mold coverage). Amphotericin B products (liposomal AmBisome, deoxycholate generic) for severe infections. Echinocandins (caspofungin, micafungin generic, anidulafungin) for candidemia. Cresemba advantages: better tolerability than voriconazole, no cyclodextrin vehicle in IV, and activity against mucormycosis (which voriconazole lacks).
What is Cresemba Prescription Assistance Program?
The Cresemba Patient Assistance Program is a manufacturer-sponsored initiative that helps eligible patients access Cresemba (used for invasive aspergillosis and mucormycosis in adults and pediatric patients 1 year and older) at little or no cost when they meet specific income, insurance, and clinical criteria. The program is free to apply for, but enrollment involves detailed applications, infectious disease coordination, diagnostic documentation, and ongoing renewal.
At AffordMyPrescriptions, our Patient Advocates handle the entire Cresemba PAP enrollment for a flat $69.95 per month. We complete the application, coordinate with your infectious disease specialist for required documentation, follow up with the manufacturer’s program until approval, manage your refills, and handle annual re-certification.
AffordMyPrescriptions eliminates that burden. For a flat $69.95 per month, our Patient Advocates handle every step of your Cresemba enrollment — from the initial application through ongoing refills and re-enrollment — so you never face a gap in your invasive fungal infection treatment.
Pharmacy Price Comparison
- Without assistance, Cresemba costs thousands of dollars per month at specialty pharmacies. A Patient Assistance Program can make this triazole antifungal accessible if you qualify:
| PHARMACY | PRICE (30-DAY) WITH BEST COUPONS | YOU SAVE W/ US |
|---|---|---|
| Generic posaconazole (alt) | ~$800/mo | Generic alt triazole |
| Walgreens | ~$9,500/mo | Save substantially |
| CVS Pharmacy | ~$10,000/mo | Save substantially |
| Walmart | ~$7,000/mo | Save substantially |
| Specialty pharmacy | ~$6,000/mo | Save substantially |
| Generic voriconazole (alt) | ~$300/mo | Generic alt for aspergillosis |
*Retail prices are estimates based on public data and vary by pharmacy. Coupon prices from GoodRx and SingleCare as of April 2026. AffordMyPrescriptions Advocacy Service bypasses pharmacy pricing entirely by using the manufacturer’s assistance program to secure your Cresemba — independent of dosage or retail price.
Our Pricing:
$69.95 Per month
1 Medications
$79.95 Per Month
2 Medications
$89.95 Per Month
3 Medications
$99.95 Per Month
4+ Medications
Why choose us For Your Cresemba Prescription Program?
The Cresemba Patient Assistance Program is free to apply and provides medication at no cost if approved. Our $69.95 per month covers full advocacy. Generic voriconazole and posaconazole are cheaper alternatives — but Cresemba’s advantages (mucormycosis coverage, better tolerability, no cyclodextrin vehicle in IV) make it appropriate for specific patients.
Enroll
Complete a simple eligibility form so our team can determine if you may qualify for Cresemba assistance.
We Advocate
Our specialists gather documentation, complete applications, and coordinate with your prescriber and the assistance program.
Receive Medication
Once approved, your Cresemba is delivered through the assistance program while we manage refills and annual renewals.
Discount Coupons vs. Patient Assistance Programs
Many patients try discount cards first. Here’s why the Patient Assistance Program through AffordMyPrescriptions is the better long-term solution for Cresemba:
Limitations of Coupons
Prices fluctuate — savings aren’t guaranteed month-to-month
Copay accumulators may prevent savings from counting toward your deductible
Coupon cards expire and require constant renewal
Still $6,000–$10,000 per month even with the best discount
Cannot be used with Medicare, Medicaid, or government insurance
Advantages of PAP Through Us
Fixed $69.95/month — never changes regardless of retail price
- No expiration — continuous access as long as you qualify
Medication supplied directly through the assistance program
We manage all paperwork, refills, and annual renewals
Medicare Part D patients accepted
If denied, we explore alternative savings paths on your behalf
DO YOU QUALIFY?
Eligibility is generally determined by annual household income and insurance status. Most programs follow guidelines that include limits of up to $40,000 for individuals, $60,000 for couples, and $100,000 for larger families. Because requirements vary by program and household, we encourage you to contact AffordMyPrescriptions directly so we can review your specific situation and determine if you qualify for Cresemba assistance.
- You Are A U.S. Citizen Or Legal Resident
- You Have A Valid Cresemba Prescription From A Licensed U.S. Healthcare Provider
- You Are Uninsured, Underinsured, Or A Medicare Part D Beneficiary
- You Have Recently Experienced A Change In Financial Circumstances That Affects Your Ability To Pay
Understanding Cresemba:
Cresemba is a broad-spectrum triazole antifungal with unique activity against Mucorales (mucormycosis pathogens) — which voriconazole lacks. The prodrug (isavuconazonium) is rapidly converted to active isavuconazole. Oral and IV formulations are bioequivalent, with no cyclodextrin vehicle in the IV form, and better tolerability than voriconazole.
How It Works:
Invasive fungal infections — particularly invasive aspergillosis and mucormycosis — cause life-threatening disease in immunocompromised patients (transplant recipients, prolonged neutropenia, uncontrolled diabetes with ketoacidosis, prolonged corticosteroids). Isavuconazole inhibits fungal lanosterol 14-α-demethylase (CYP51) — disrupting ergosterol synthesis and the fungal cell membrane. It has broad-spectrum activity including Mucorales. The prodrug isavuconazonium is water-soluble for IV and hydrolyzed to active isavuconazole. A half-life of ~130 hours enables extended dosing intervals. It uses no cyclodextrin vehicle — safe in renal impairment (unlike IV voriconazole).
Form and Use:
Cresemba oral capsules 186 mg (equivalent to 100 mg isavuconazole) or IV. Loading: 372 mg every 8 hours for 6 doses (48 hours). Maintenance: 372 mg once daily starting 12–24 hours after the last loading dose. Oral or IV interchangeable. Continue per infectious disease guidance for the duration of therapy. Monitor LFTs periodically.
Generic Availability:
No generic Cresemba. Other triazole antifungals: voriconazole (Vfend — generic; gold standard for aspergillosis but with QT prolongation, hepatotoxicity, visual disturbances, extensive drug interactions), posaconazole (Noxafil — generic; broad-spectrum including Mucorales), itraconazole (Sporanox — generic), fluconazole (Diflucan — generic; limited mold coverage). Amphotericin B products (liposomal AmBisome preferred for reduced nephrotoxicity; deoxycholate — generic, more nephrotoxic) for severe infections. Echinocandins (caspofungin, micafungin — generic, anidulafungin) for candidemia primarily. Combination therapy is sometimes used for severe mucormycosis.
Warnings:
Hepatotoxicity (less than voriconazole but possible — monitor LFTs), infusion reactions (IV — slow infusion), embryo-fetal toxicity, hypersensitivity reactions including SJS/TEN (rare). Other: nausea, vomiting, diarrhea, hypokalemia, decreased appetite, elevated LFTs. QT: Cresemba does not prolong QT (a potential advantage over voriconazole; but avoid in familial short QT syndrome). Drug interactions: strong CYP3A4 inhibitors and inducers significantly affect levels; important interactions with immunosuppressants (tacrolimus, cyclosporine, sirolimus levels increased), anti-HIV agents, and others.
FAQ (Frequently Asked Questions)
How much does Cresemba cost without insurance?
$6,000–$10,000 per month. Generic voriconazole (alternative triazole for aspergillosis) costs $200–$400 per month; generic posaconazole $500–$1,000 per month.
What is the difference between Cresemba and voriconazole (Vfend)?
Both are triazole antifungals. Voriconazole (generic) is the gold standard for invasive aspergillosis but with QT prolongation, hepatotoxicity, visual disturbances, and extensive drug interactions. Cresemba has better tolerability, does not prolong QT, covers Mucorales (voriconazole does not), and its IV formulation avoids the cyclodextrin vehicle. Voriconazole is much cheaper. Cresemba is appropriate for mucormycosis, voriconazole intolerance, or renal impairment.
Why does Cresemba cover mucormycosis but voriconazole doesn't?
Voriconazole lacks activity against Mucorales (Rhizopus, Mucor, and other mucormycosis pathogens) — a critical gap in severely immunocompromised patients. Cresemba and posaconazole cover Mucorales. Amphotericin B (liposomal formulation preferred) is often first-line for severe mucormycosis; Cresemba may be a step-down oral therapy.
Is the Cresemba capsule the same as IV?
Yes — oral and IV formulations are bioequivalent with the same dosing. Switching between routes is straightforward without dose adjustment — an advantage over voriconazole, where oral bioavailability is variable and IV cyclodextrin is problematic in renal impairment.
What are the major drug interactions with Cresemba?
Cresemba is metabolized by CYP3A4 and is a moderate CYP3A4 inhibitor. Strong CYP3A4 inhibitors increase levels; inducers (rifampin, phenytoin, carbamazepine, St. John’s wort) decrease levels — contraindicated with rifampin. It increases levels of immunosuppressants (tacrolimus, cyclosporine, sirolimus) requiring dose adjustment. Pharmacist review is essential.
Take Control of Your Medication Costs
Invasive fungal infection therapy should not be derailed by cost — Cresemba’s unique mucormycosis coverage and better tolerability can be lifesaving. Our advocacy team is ready — for a flat $69.95 per month. If we cannot help you access Cresemba, you are not charged.
Submit Enrollment Form
Start free by filling out a simple online form.
Receive Welcome Call
Our specialist will contact you for a quick welcome call.
We Manage The Process
Our team handles everything, so you can focus on your health.